Filament Health Corp. (FH.NE)
| Previous Close | 0.0350 |
| Open | 0.0350 |
| Bid | 0.0400 x N/A |
| Ask | 0.0450 x N/A |
| Day's Range | 0.0350 - 0.0400 |
| 52 Week Range | 0.0300 - 0.2000 |
| Volume | |
| Avg. Volume | 61,449 |
| Market Cap | 10.248M |
| Beta (5Y Monthly) | 1.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
CNW GroupFILAMENT HEALTH ANNOUNCES ISSUANCE OF COMMON SHARES TO NEGEV CAPITAL INVESTMENTS LIMITED PURSUANT TO ADVISORY AGREEMENT
Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announces that, it has issued 5,600,000 common shares in the capital of the Company (the "Common Shares") at a price of $0.05 per Common Share to Filament Health SPV – Allocations Funds LLC, Bioconnect Ventures – Allocations Funds LLC, and Sovereign74, LLC. The Common Shares are being issued to pursuant to an advisory agreement (the "Ad
CNW GroupFILAMENT HEALTH ANNOUNCES SECOND QUARTER 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its second quarter financial results and operational highlights for the period ended June 30, 2024.
CNW GroupFILAMENT HEALTH ANNOUNCES MAJOR INTELLECTUAL PROPERTY EXPANSION
Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that it has expanded its intellectual property (IP) portfolio with the acceptance of twelve patents by IP Australia for processes relating to the development of botanical psychedelic drugs. Filament has been issued a further five patents by the Canadian Intellectual Property Office (CIPO), and three patents by the United State
